Virtual Symposium - Addressing the Impacts of Iron Deficiency in HF: Advances in Diagnosis and Management

Iron deficiency (ID) affects up to one-third of the world's population and is particularly common in elderly individuals and those with heart failure (HF). Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with HF, ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients.

In this symposium, experts will discuss data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. Recent updates to established HF treatment guidelines that emphasize ID recognition and treatment will also be addressed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.

Target Audience

This activity is designed for US-based healthcare professionals, including cardiologists, endocrinologists, primary care clinicians (PCPs), pharmacists, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review the prevalence and clinical burden of iron deficiency in HF patients
  • List current and emerging diagnostic approaches aimed to optimize the early diagnosis of ID in patients with HF
  • Interpret data about the efficacy and safety of intravenous iron repletion for the treatment of iron deficiency in HF patients
  • Identify individualized treatment regimens to manage ID in HF patients, including the administration of intravenous iron, based on the current evidence and guideline recommendations
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Course opens: 
03/01/2021
Course expires: 
03/31/2022
Rating: 
0

Anne L. Peters, MD (Chair)
Professor, Keck School of Medicine
Director, Clinical Diabetes Programs
University of Southern California
Los Angeles, CA

Dr. Peters discloses the following: 

Participation on an advisory board for: Abbott Diabetes Care, Boehringer Ingelheim, Eli Lilly and Company, Livongo, MannKind, Merck, Novo Nordisk, Sanofi, Pendulum Therapeutics

Research Support: Dexcom, vTvTherapeutics, and donated devices from Abbott Diabetes Care

Speaker’s Bureau: Novo Nordisk

Stock Options: Mellitus Health, Omada Health, Stability Health, Pendulum Therapeutics, Livongo

 

Irl B. Hirsch, MD
Professor of Medicine
Diabetes Treatment and Teaching Chair
University of Washington Medical Center
Medical Director
UWMC Diabetes Care Center
Seattle, WA

Dr. Hirsch discloses: 

Consulting Fees: Abbott, BigFoot

Contracted Research: Medtronic, Insulet

 

Athena Philis-Tsimikas, MD
Corporate Vice President
Scripps Whittier Diabetes Institute
San Diego, CA

Dr. Philis-Tsimikas discloses the following: 

Salary (Spouse): Ionis

Contracted Research: Dexcom, Lilly, Novo, Sanofi

ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hour

EDUCATIONAL GRANT SUPPORT
This educational activity is supported by an educational grant from American Regent.

JOINT ACCREDITATION STATEMENT
image   image   image



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. 

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledged-based activity. Universal Activity Numbers (UAN): #XXX

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period April X, 2021 through April X, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.

For questions about the accreditation of this activity, please visit www.pimed.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.